Last reviewed · How we verify
SARS-CoV-2 Bivalent mRNA Vaccine
At a glance
| Generic name | SARS-CoV-2 Bivalent mRNA Vaccine |
|---|---|
| Also known as | LVRNA021 |
| Sponsor | AIM Vaccine Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Lymph Node Aspiration to Decipher the Immune Response of Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine. (NA)
- COVID-19 Booster Study in Healthy Adults in Australia (PHASE3)
- Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers (EARLY_PHASE1)
- Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants (PHASE2)
- Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern (PHASE2, PHASE3)
- Korea Comirnaty Post-marketing Surveillance
- To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age. (PHASE3)
- COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SARS-CoV-2 Bivalent mRNA Vaccine CI brief — competitive landscape report
- SARS-CoV-2 Bivalent mRNA Vaccine updates RSS · CI watch RSS
- AIM Vaccine Co., Ltd. portfolio CI